Einzeltreffer — DigiBib

Precision medicine has helped identify several tumor molecular aberrations to be treated with targeted therapies. These therapies showed substantial improvement in efficacy without excessive toxicity in patients with specific oncogenic drivers with advanced cancers. In metastatic lung cancers, the implementation of broad platforms for molecular tumor sequencing has helped oncology providers identify oncogenic drivers linked with better outcomes when treated upfront with targeted therapies. Mesenchymal-epithelial transition factor (MET) alterations are present in up to 60% of non-small cell lung cancer and are associated with a poor prognosis. Capmatinib and tepotinib are currently the only two approved targeted therapies by the U.S. Food and Drug Administration (FDA) for patients with MET exon 14 skipping mutation. Several agents are being developed to tackle an unmet need in patients with MET alterations. Some of these agents are being used in combination with EGFR targeted therapy to mitigate resistance to EGFR inhibitor. These agents are poised to provide new hope for these patients.

Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Titel:	MET alterations in advanced non-small cell lung cancer.
Autor/in / Beteiligte Person:	Chagas, GCL ; Rangel, AR ; El Osta, B
Zeitschrift:	Current problems in cancer, Jg. 49 (2024-04-01), S. 101075
Veröffentlichung:	St. Louis : Mosby ; <i>Original Publication</i>: Chicago, Year Book Medical Publishers., 2024
Medientyp:	academicJournal
ISSN:	1535-6345 (electronic)
DOI:	10.1016/j.currproblcancer.2024.101075
Schlagwort:	Humans Protein Kinase Inhibitors therapeutic use Molecular Targeted Therapy methods Antineoplastic Agents therapeutic use Precision Medicine methods Carcinoma, Non-Small-Cell Lung drug therapy Carcinoma, Non-Small-Cell Lung genetics Carcinoma, Non-Small-Cell Lung pathology Proto-Oncogene Proteins c-met genetics Proto-Oncogene Proteins c-met antagonists & inhibitors Lung Neoplasms pathology Lung Neoplasms drug therapy Lung Neoplasms genetics Mutation
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Review Language: English [Curr Probl Cancer] 2024 Apr; Vol. 49, pp. 101075. <i>Date of Electronic Publication: </i>2024 Mar 13. MeSH Terms: Carcinoma, Non-Small-Cell Lung* / drug therapy ; Carcinoma, Non-Small-Cell Lung* / genetics ; Carcinoma, Non-Small-Cell Lung* / pathology ; Proto-Oncogene Proteins c-met* / genetics ; Proto-Oncogene Proteins c-met* / antagonists & inhibitors ; Lung Neoplasms* / pathology ; Lung Neoplasms* / drug therapy ; Lung Neoplasms* / genetics ; Mutation* ; Humans ; Protein Kinase Inhibitors / therapeutic use ; Molecular Targeted Therapy / methods ; Antineoplastic Agents / therapeutic use ; Precision Medicine / methods Contributed Indexing: Keywords: MET amplification; MET exon 14 skipping mutation; MET overexpression; Non-small cell lung cancers (NSCLC); Precision oncology; Targeted therapy; c-MET alterations Substance Nomenclature: EC 2.7.10.1 (Proto-Oncogene Proteins c-met) ; EC 2.7.10.1 (MET protein, human) ; 0 (Protein Kinase Inhibitors) ; 0 (Antineoplastic Agents) Entry Date(s): Date Created: 20240313 Date Completed: 20240427 Latest Revision: 20240427 Update Code: 20240428

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

MET alterations in advanced non-small cell lung cancer.